Colloidal Chromic Phosphate: its Biological Behaviour

Summary

The distribution within the body of various types of colloidal chromic phosphate (⁵¹Cr³²PO₄) at different times after intravenous and intraperitoneal injection has been studied. The possible hydrolysis “in situ” of the chromic phosphate was determined by studying the ratio β-activity / γ-activity. Similar studies have been performed with the different fractions of bone. The true colloidal chromic phosphate — in contrast to the particulated one — migrates in 50% of the cases to the liver 24 h after intraperitoneal administration. This behavior indicates the usefulness of this type of preparation for postoperative tumor prophylaxis.

La distribution dans le corps des phosphates chromiques colloïdales (⁵¹Cr³²PO₄) des types différents en fonction du temps a été étudiée après l’injection intraveineuse et intrapéritonéale. L’hydrolyse probable du phosphate chromique „in situ“ fut déterminée par le quotient activité β / activité γ. Des études semblables ont été effectuées pour les fractions ossales différentes. Le vrai phosphate chromique colloïdal — contrairement à celui d’une nature corpusculaire —, dans 50% des cas, se trouve dans le foie 24 h après l’injection intrapéritonéale. Ce comportement indique l’utilité de cette préparation pour la prophylaxie postopérative des tumeurs.

Es wurde die Verteilung einiger Chromphosphat-Präparate (⁵¹Cr³²PO₄) zu verschiedenen Zeitpunkten nach intravenöser und intraperitonealer Injektion untersucht. Aus der Relation β-Aktivität / γ-Aktivität ergibt sich eine wahrscheinliche Hydrolyse des Chromphosphats „in situ“. Es wurde eine systematische Trennung der verschiedenen Fraktionen im Knochen durchgeführt. Die intraperitoneal injizierte kolloidale Lösung lagert sich — im Gegensatz zum Chromphosphat in Partikelform — in 50% der Fälle nach 24 h in der Leber ab. Diese Ablagerung des Radiokolloids bietet die Möglichkeit einer prophylaktischen postoperativen Tumorbehandlung.

^* Present address: The John’s Hopkins Medical Institutions, Department of Radiological Science, Baltimore, Maryland USA.

• References

• 1 Jaffe H. L. Treatment of malignant serous effusions with radioactive colloidal chromic phosphate. Amer. J. Roentgenol 74: 657 1955;
• 2 Kutzim H. Zur Therapie mit Chromphosphatsuspensionen. Atomkernenergie 4: 276 1955;
• 3 Rusche C. F, Jaffe H. L. Palliative treatment of prostatic cancer with radioactive colloidal chromic phosphate: Three years experience and results. Amer. J. Roentgenol 74: 393 1955;
• 4 Rusche C. F, Jaffe H. L. Treatment of prostatic carcinoma with radioactive colloidal chromic phosphate (P-32), a preliminary report. J. Urol. (Baltimore) 72: 466 1954;
• 5 Moore V, Gamble D, Libby R. L, Goodwin W. E. Radioactive chromic phosphate in the treatment of urologie tumours. J. Urol. (Baltimoore) 73: 410 1955;
• 6 Chevalier A, Burg C. The use of colloidal chromic radiophosphate in the treatment of malignant tumours. Proceedings, International Conference on Peaceful Uses of Atomic Energy 10: 115 1956;
• 7 Root S. W, Tylor M. P, Andrews G. A, Kniseley R. M. Distribution of colloidal radioactive chromic phosphate after intracavitary administration. Radiology 63: 251 1954;
• 8 Lange R. H, Shields J. L, Rozendaal H. M. Colloidal radioactive chromic phosphate in the control of malignant effusions. N. Y. St. J. Med 56: 1928 1956;
• 9 Jacobs M. L. Use of radioactive chromic phosphate in pleural effusions. Calif. Med 81: 268 1954;
• 10 Harper P. V, Lathrop K. A. Recent advances in the therapeutic use of radioisotopes in surgery. Surg. Clin. N. Amer 39: 65 1959;
• 11 McFee A. S, Ackerman N. B, Loken M. K. The prevention of hepatic metastasis by the use of colloidal suspension of radioactive chromic phosphate. J. Nucl. Med 4: 234 1963;
• 12 Ackerman N. B, McFee A. S, Loken M. K. Prevention of liver metastases by intravenous radioisotopes: Use of P-32 labeled chromic phosphate. J. Amer. Med. Ass 187: 826 1964;
• 13 Burger R. H, Asano M, Nagamatsu G. R. Intralymphatic isotopes for radiation of node metastases. Investig. Urol 2: 215 1964;
• 14 Burger R. H. Lymph node response to high-dose intralymphatic injection of radiochromic phosphate. Bull. N. Y. Acad. Med 40: 142 1964;
• 15 Dobson E. L, Finkelstein L. J, Finney C. R, Kelly L. S. Particulate chromic phosphate: Colloid characteristics suitable for measurement of liver circulation. Radioactive Pharmaceuticals, Atomic Energy Commission Symposion Series 6: 477 1966;
• 16 Jones H. B, Wrabel C. J, Lyons W. R. J. Clin. Invest 23: 783 1944;
• 17 Anghileri L. J. Rapid method for obtaining colloidal suspensions of P-32 as chromic phosphate. Proceedings of the Second United Nations Conference for Peaceful Uses of Atomic Energy. Geneva: 1958. Conference Paper No. P/1575.
• 18 Anghileri L. J. In Vivo distribution of radioactive chromic phosphate: Influence of the particle size and route of injection. Int. J. Appl. Radiat 16: 623 1965;
• 19 Anghileri L. J. In Vitro effects on different tissues of colloidal chromic phosphate (³²P). Naturwissenschaften 14: 429 1965;
• 20 Anghileri L. J, Marques R. Stability of the colloidal chromic radiophosphate (³²P) to the isotopic exchange. Experientia 22: 522 1966;